130 related articles for article (PubMed ID: 11710996)
1. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions.
Yanai Y; Sanou O; Kayano T; Ariyasu H; Yamamoto K; Yamauchi H; Ikegami H; Kurimoto M
J Interferon Cytokine Res; 2001 Oct; 21(10):835-41. PubMed ID: 11710996
[TBL] [Abstract][Full Text] [Related]
2. In vitro sensitivity of human metapneumovirus to type I interferons.
Scagnolari C; Trombetti S; Selvaggi C; Carbone T; Monteleone K; Spano L; Di Marco P; Pierangeli A; Maggi F; Riva E; Antonelli G
Viral Immunol; 2011 Apr; 24(2):159-64. PubMed ID: 21449726
[TBL] [Abstract][Full Text] [Related]
3. Comparison of an antiviral activity of recombinant consensus interferon with recombinant interferon-alpha-2b.
Koyama AH; Arakawa T; Adachi A
Microbes Infect; 1999 Nov; 1(13):1073-7. PubMed ID: 10572309
[TBL] [Abstract][Full Text] [Related]
4. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
Ozes ON; Reiter Z; Klein S; Blatt LM; Taylor MW
J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
[TBL] [Abstract][Full Text] [Related]
5. Creation of interferon-alpha8 mutants with amino acid substitutions against interferon-alpha receptor-2 binding sites using phage display system and evaluation of their biologic properties.
Yamamoto K; Taniai M; Torigoe K; Yamamoto S; Arai N; Suemoto Y; Yoshida K; Okura T; Mori T; Fujioka N; Tanimoto T; Miyata M; Ariyasu H; Ushio C; Fujii M; Ariyasu T; Ikeda M; Ohta T; Kurimoto M; Fukuda S
J Interferon Cytokine Res; 2009 Mar; 29(3):161-70. PubMed ID: 19196068
[TBL] [Abstract][Full Text] [Related]
6. Chicken interferon types I and II enhance synergistically the antiviral state and nitric oxide secretion.
Sekellick MJ; Lowenthal JW; O'Neil TE; Marcus PI
J Interferon Cytokine Res; 1998 Jun; 18(6):407-14. PubMed ID: 9660248
[TBL] [Abstract][Full Text] [Related]
7. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency.
Foster GR; Rodrigues O; Ghouze F; Schulte-Frohlinde E; Testa D; Liao MJ; Stark GR; Leadbeater L; Thomas HC
J Interferon Cytokine Res; 1996 Dec; 16(12):1027-33. PubMed ID: 8974005
[TBL] [Abstract][Full Text] [Related]
8. Biological basis for a proper clinical application of alpha interferons.
Antonelli G
New Microbiol; 2008 Jul; 31(3):305-18. PubMed ID: 18843884
[TBL] [Abstract][Full Text] [Related]
9. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
Khine AA; Lingwood CA
J Cell Physiol; 2000 Jan; 182(1):97-108. PubMed ID: 10567921
[TBL] [Abstract][Full Text] [Related]
10. WISH cell line: from the antiviral system to a novel reporter gene assay to test the potency of human IFN-α and IFN-β.
Bürgi Mde L; Prieto C; Etcheverrigaray M; Kratje R; Oggero M; Bollati-Fogolín M
J Immunol Methods; 2012 Jul; 381(1-2):70-4. PubMed ID: 22549076
[TBL] [Abstract][Full Text] [Related]
11. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
[TBL] [Abstract][Full Text] [Related]
12. Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation.
Zhao HL; Xue C; Wang Y; Li XY; Xiong XH; Yao XQ; Liu ZM
J Biotechnol; 2007 Sep; 131(3):245-52. PubMed ID: 17698234
[TBL] [Abstract][Full Text] [Related]
13. Development of a highly purified multicomponent leukocyte IFN-alpha product.
Tölö H; Kauppinen HL; Alm G; Perers A; Lindeberg E; Wahlstedt-Fröberg V; Parkkinen J
J Interferon Cytokine Res; 2001 Nov; 21(11):913-20. PubMed ID: 11747623
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.
Scagnolari C; Antonelli G
Expert Opin Biol Ther; 2013 May; 13(5):693-711. PubMed ID: 23350850
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the biological activities and physicochemical characteristics of recombinant bovine interferon-α₁₄.
Shao J; Cao C; Bao J; Gao M; Wang J
Mol Immunol; 2015 Mar; 64(1):163-9. PubMed ID: 25480392
[TBL] [Abstract][Full Text] [Related]
16. ELISA measurement of interferons.
Garrison TL; Hung F; Izotova L; Schwartz B; Lavoie T; Lee-Own FV
Biotechniques; 2002 Oct; Suppl():98-100. PubMed ID: 12395933
[No Abstract] [Full Text] [Related]
17. Cloning, expression and antiviral activity of mink alpha-interferons.
Zhang HL; Zhao JJ; Chai XL; Zhang L; Bai X; Hu B; Liu H; Zhang DL; Ye M; Wu W; Yan XJ
BMC Vet Res; 2015 Feb; 11():42. PubMed ID: 25889984
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of antiviral activity between FeIFN-omega and FeIFN-alpha].
Wang H; Jia X; Yang L; Sun L; Wang H; Liu W
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1556-60. PubMed ID: 19160837
[TBL] [Abstract][Full Text] [Related]
19. Effect of amino acids on the expression of antiviral activity of different types of human interferon. I. Effect of single amino acids.
Tóth S; Mécs I
Acta Microbiol Hung; 1985; 32(4):363-8. PubMed ID: 3012929
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anticellular and antiviral activities of human recombinant interferon-gamma and -beta.
Gomi K; Kimura H; Okabe M; Oka T; Morimoto M
J Pharmacobiodyn; 1986 Nov; 9(11):871-8. PubMed ID: 3031263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
